牛牛AI助理已提取核心讯息微创心通医疗科技预计2025年上半年净亏损不超过人民币1000万元,较2024年同期大幅减少83%以上。业绩改善主要受益于VitaFlow Liberty®产品在海外20余个国家实现销售,海外收入同比增长超过两倍;同时AnchorMan®左心耳封堵器系统在中国市场稳步推进,并已获得CE认证进入欧洲市场。集团通过优化资源配置、加强费用管控等措施持续提升运营效率。此外,集团...
Source Link牛牛AI助理已提取核心讯息微创心通医疗科技预计2025年上半年净亏损不超过人民币1000万元,较2024年同期大幅减少83%以上。业绩改善主要受益于VitaFlow Liberty®产品在海外20余个国家实现销售,海外收入同比增长超过两倍;同时AnchorMan®左心耳封堵器系统在中国市场稳步推进,并已获得CE认证进入欧洲市场。集团通过优化资源配置、加强费用管控等措施持续提升运营效率。此外,集团...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.